In Today’s very special Featured Company update we sit down with James Lanthier (CEO, Mindset Pharma) to discuss a recent letter sent to shareholders which outlined significant talking points clarifying their direction and focus. Find out what’s in store for this grass roots up and coming Biotech company for the rest of 2022. Don’t miss out!
About Mindset Pharma
Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded in 2019 by domain experts in drug development, medicinal chemistry and capital markets, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely. Classic psychedelics will likely be approved for medical use in the near future, however, they are not optimized as pharmaceuticals and cannot be patented as they are in the public domain .Mindset is applying innovative medicinal chemistry to create a pipeline of optimized psychedelic medications with improved efficacy and reduced toxicity. Mindset has developed a patent-pending chemical synthesis process to address a pressing need for scalable, pharmaceutical grade, low-cost psilocybin
